1.00Open1.00Pre Close0 Volume610 Open Interest200.00Strike Price0.00Turnover66.82%IV14.65%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier10DDays to Expiry1.00Extrinsic Value100Contract SizeAmericanOptions Type-0.0792Delta0.0055Gamma233.15Leverage Ratio-0.1784Theta-0.0053Rho-18.47Eff Leverage0.0588Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet